Ardelyx Launches Irritable Bowel Syndrome Treatment Ibsrela

April 4, 2022

Several years following FDA approval, Ibsrela® (tenapanor) oral tablets are now available to treat irritable bowel syndrome with constipation (IBS-C) in adults.

  • Ibsrela is a first-in-class treatment for IBS-C that received FDA approval on September 12, 2019. However, manufacturer Ardelyx has only recently launched the product.
  • Recommended dosing is 50mg taken twice daily by mouth: once immediately prior to breakfast or the first meal of the day, and once immediately prior to dinner.
  • The wholesale acquisition cost (WAC) is $1,500 per 60 tablets.
demo-attachment-261-Group-56
demo-attachment-606-Group-43
demo-attachment-1121-Rectangle-602

Benefit Advisors & Employees - Want to know more?

Members: Please call the number on the back of your ID card or e-mail member.services@benecardpbf.com Clients: Contact your Client Relations Manager
demo-attachment-180-Group-4